Results of benign prostate hyperplasia published in World Journal of Urology.
Nymox Pharmaceutical reports that the results of Phase III clinical studies of REC 0482 (fexapotide triflutate) in Benign Prostate Hyperplasia undertaken from 2009-2016 are now published in World Journal of Urology. According to the publication, data from 4 U.S. studies show statistically significant long-term improvement in BPH symptoms and objective outcomes including significant reduction in spontaneous AUR as well as the addition of BPH surgery. FT was well tolerated with an excellent safety profile. The Company has filed for approval for Fexapotide in Europe for BPH for prostate enlargement in 2017, and the filing was validated in September 2017.
See: "Fexapotide Triflutate: Results of Long-Term Safety and Efficacy Trials of a Novel Injectable Therapy for Symptomatic Prostate Enlargement Neal Shore et al. World Journal of Urology, First Online: 29 January 2018 https://doi.org/10.1007/s00345-018-2185-y
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.